

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Glycorex Transplantation AB	
Application No./Patent No.: 09/750,280	Filed/Issue Date: 29 December 2000
Entitled: Trifunctional Reagent for Conjugation to a Biomolecule	

Glycorex Transplantation AB (Assignee), a Company of Sweden (Entity type)

states that it is:

- ☒ the assignee of the entire right, title, and interest; or
- ☐ an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is 100 %

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel/Frame , on .

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

Assignment: 1

Reel/Frame: 011716/0224

Recorded: 04/18/2001

Pages: 3

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors: WILBUR, D. SCOTT

Exec Dt: 01/20/2001

SANDBERG, BENGT E.B.

Exec Dt: 02/12/2001

Assignees: DEPARTMENT OF RADIATION ONCOLOGY, UNIVERSITY OF WASHINGTON

MAILSTOP 358750

2121 NORTH 35TH STREET

SEATTLE, WASHINGTON 98103

MITRA MEDICAL TECHNOLOGY AB OF IDEON RESEARCH PARK

MAILSTOP 358750

2121 NORTH 35TH STREET

223 70 LUND, SWEDEN

Correspondent: SMITH, GAMBRELL & RUSSELL, LLP

MICHAEL K. CARRIES

1850 M. ST NW (STE 800)

WASHINGTON, DC 20036

Assignment: 2

Reel/Frame: 020559/0045

Recorded: 02/26/2008

Pages: 6

Conveyance: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

Assignor: MITRA MEDICAL TECHNOLOGY AB

Exec Dt: 10/20/2004

Assignee: MITRA MEDICAL AB

FORSKARBYN IDEON

LUND, SWEDEN 223 70

Correspondent: SWANSON & BRATSCUN, LLC


8210 SOUTHPARK TERRACE

Assignment: 3**Reel/Frame:** 020510/0725**Recorded:** 02/14/2008**Pages:** 5**Conveyance:** ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).**Assignor:** MITRA MEDICAL AB**Exec Dt:** 01/14/2008**Assignee:** BIOTECH IGG ABSCHEELEVAGEN 17
LUND, SWEDEN S-223 70**Correspondent:** SWANSON & BRATSCHUN, LLC
8210 SOUTHPARK TERRACE
LITTLETON, CO 80120**Assignment: 4**

From Biotech IGG AB to Glycorex Transplantation AB via a Patent Transfer Agreement dated 12 November 2008 which is attached herewith.

[NOTE: A separate copy (*i.e.*, a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Name:	Suzannah K. Sundby		
Signature:		Date:	7 July 2009
Title:	Attorney of Record, Reg. No. 43,172	Telephone:	202-263-4332



PATENT TRANSFER AGREEMENT

Biotech-IgG AB, company registration No. 556713-5818, located at Forskningsbyn Ideon, 223 70 Lund, Sweden, was declared bankrupt by the District Court of Lund, Sweden, on 26th June 2008. The court appointed Mr Bo Svensson at the lawfirm Advokatfirman Glimstedt as a official receiver in the bankruptcy. The bankruptcy estate of Biotech-IgG AB in bankruptcy, represented by its official receiver, has now entered the following agreement with Glycorex Transplantation AB.

Biotech-IgG AB's bankruptcy estate, located at c/o Advokatfirman Glimstedt, P O Box 1246, 221 05 Lund, Sweden – hereinafter referred to as “the Seller” –

and,

Glycorex Transplantation AB, company registration No. 556519-7372, located at Sölvegatan 41, 223 70 Lund, Sweden – hereinafter referred to as “the Buyer” –

has agreed as follows.

The Seller hereby sells and assigns to the Buyer the patent and patent applications listed in Enclosure A - hereinafter referred to as “the Patent Rights”. The assignment also includes all assignable rights derived from the Patent Rights including, without limitation, the right to the claimed inventions, the right to claim priority, and the right to file divisional patent application and take similar actions.

The Buyer shall be responsible for the recording of the assignment of the Patent Rights. The Seller's obligations in this respect is limited to, at the request of the Buyer, without any cost for the Buyer, signing all documents prepared by the Buyer and reasonably required in order to record the assignment with the appropriate authorities and to do such other acts as necessary to give full effect to the terms of this agreement.




ADVOKATFIRMAN
GLIMSTEDT

This agreement shall be governed by Swedish law. Any dispute in connection with this Agreement shall be referred to the District Court of Lund, Sweden.


Lund 12th November 2008

Biotech-IgG AB's bankruptcy estate



Bo Svensson
Official Receiver

Glycorex Transplantation AB



/Kurt Nilsson/
President and CEO

Property Category Sub Type	Applicant/Owner Type of Mark Your Reference / Trademark	Pending Duration	Registration Date	App No Class	File No Country	Handled by	Status
Patient Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB	2008-12-12 2023-12-12	2008-12-12	2005-267151	21020170 Australia	DH	Pending
Patient Normal via PCT National Phase	ANTI LYMPHOMA-PC-AU						
Patient Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB	2008-12-12 2023-12-12	2008-12-12	2 506 103	21020172 Canada	DH	Pending
Patient Normal via PCT National Phase	ANTI LYMPHOMA-PC-CA						
Patient Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB		2003-12-12	200387100743.0	21020173 China	DH	Pending
Patient Normal via PCT National Phase	ANTI LYMPHOMA-PC-CN						
Patient Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB	2004-12-31 2023-12-12	2003-12-12	03781200.5	21020175 European Patent Office	DH	Pending
Patient Normal via PCT National Phase	ANTI LYMPHOMA-PC-EP						
Patient Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB		2003-12-12	169082	21020177 Israel	DH	Pending
Patient Normal via PCT National Phase	ANTI LYMPHOMA-PC-IL						
Patient Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB		2003-12-12	312777CHEN/200	21020176 India	DH	Pending
Patient Normal via PCT National Phase	ANTI LYMPHOMA-PC-IN						
Patient Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB		2004-12-12	2004-660221	21020178 Japan	DH	Pending
Patient Normal via PCT National Phase	ANTI LYMPHOMA-PC-JP						
Patient Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB		2003-12-12	2005-7010611	21020174 Republic of Korea	DH	Pending
Patient Normal via PCT National Phase	ANTI LYMPHOMA-PC-KR						
Patient Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB		2003-12-12	P4642005006306	21020179 Mexico	DH	Pending
Patient Normal via PCT National Phase	ANTI LYMPHOMA-PC-MX						
Patient Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB	2008-12-31 2023-12-12	2008-12-12	2002-2842	21020180 Norway	DH	Pending
Patient Normal via PCT National Phase	ANTI LYMPHOMA-PC-NO						
Patient Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB		2002-12-12	377 213	21020418 Poland	DH	Pending
Patient Normal via PCT National Phase	ANTI LYMPHOMA-PC-PL						
Patient Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB		2003-12-12	2005122053	21020181 Russian Federation	DH	Pending
Patient Normal via PCT National Phase	ANTI LYMPHOMA-PC-RU						

Property Category Sub Type	Applicant/Owner Type of Mark Your Reference / Trademark	Remand Duration	Filing Date	Appl. No. Reg. No. Classes	File No. Country	Handled by	Status
Patent Normal Via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB		2003-12-12	100336-659	21020182 United States of America	DH	Pending
Patent Normal Via PCT National Phase	ANTI LYMPHOMA-PC-US						
Patent Normal Via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB DEPARTMENT OF RADIATION ON	2008-07-07 2019-02-07	1999-07-07	2 335 735	20005373 Canada	DH	Pending
Patent Normal Via PCT National Phase	BIOMOLECULES-PC-CA						
Patent Normal Via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB DEPARTMENT OF RADIATION ON	2008-06-31 2019-02-07	1999-07-07	39963251.1	20022676 European Patent Office	DH	Pending
Patent Normal Via PCT National Phase	BIOMOLECULES-PC-EP						
Patent Normal Via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB DEPARTMENT OF RADIATION ON		1999-07-07	2000-688395	2002574 Japan	DH	Pending
Patent Normal Via PCT National Phase	BIOMOLECULES-PC-JP						
Patent Normal Via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB DEPARTMENT OF RADIATION ON	2008-07-31 2019-02-07	1999-07-07	2301 0021	2002575 Norway	DH	Pending
Patent Normal Via PCT National Phase	BIOMOLECULES-PC-NO						
Patent Normal Via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB DEPARTMENT OF RADIATION ON		1999-07-07	00755 280	2002572 United States of America	DH	Pending
Patent Normal Via PCT National Phase	BIOMOLECULES-PC-US						
Patent Normal Via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB OFFICE OF TECHNOLOGY TRANSFER, UNIVER		1999-07-07	11159 955	21022414 United States of America	DH	Pending
Patent Normal Via PCT National Phase	BIOMOLECULES-PC-US-CN						
Patent Normal Via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB DEPARTMENT OF RADIATION ON		2001-06-16	006851 213	21002570 United States of America	DH	Pending
Patent Normal Via PCT National Phase	BIOTIN DERIVATIVES-P-US						
Patent Normal Via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB DEPARTMENT OF RADIATION ON	2009-06-18 2021-06-18	2001-06-18	2001 274781	21001948 Australia	DH	Registered
Patent Normal Via PCT National Phase	BIOTIN DERIVATIVES-PC-AU						
Patent Normal Via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB DEPARTMENT OF RADIATION ON	2009-06-18 2021-06-18	2001-06-18	2 412 495	21001350 Canada	DH	Pending
Patent Normal Via PCT National Phase	BIOTIN DERIVATIVES-PC-CA						
Patent Normal Via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB DEPARTMENT OF RADIATION ON		2001-06-16	812344.2	21001351 China	DH	Pending
Patent Normal Via PCT National Phase	BIOTIN DERIVATIVES-PC-CN						
Patent Normal Via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB DEPARTMENT OF RADIATION ON	2009-06-30 2021-06-18	2001-06-18	01541404.4	21001352 European Patent Office	DH	Pending
Patent Normal Via PCT National Phase	BIOTIN DERIVATIVES-PC-EP						

Property Category Sub Type	Applicant/Owner Type or Mark Your Reference/Trademark	Res. date Duration	Filing date Reg. date	Appl. No. Reg. No.	File No. Country	Handled by	Status
Patent	MITRA MEDICAL TECHNOLOGY AB/DEPARTMENT OF RADIATION ONC	2011-06-18	2001-05-18	155 419	21001854		Registered
Normal via PCT National Phase		2021-06-18	2009-04-07	155 419	Israel		
Patent	BIOTIN DERIVATIVES-PC-L						
Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB/DEPARTMENT OF RADIATION ONC/OLOGY, UNIV		2001-05-18	2002-510039	21001255		Pending
					Japan		
Patent	BIOTIN DERIVATIVES-PC-JP						
Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB/DEPARTMENT OF RADIATION ONC/OLOGY, UNIV		2001-05-18	2002-012439	21001256		Pending
					Mexico		
Patent	BIOTIN DERIVATIVES-PC-MX						
Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB/DEPARTMENT OF RADIATION ONC	2009-05-30	2001-05-18	2002 0331	21001357		Pending
		2021-05-18			Norway		
Patent	BIOTIN DERIVATIVES-PC-NO						
Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB/DEPARTMENT OF RADIATION ONC/OLOGY, UNIV		2001-05-18	P 359 328	21001358		Pending
					Poland		
Patent	BIOTIN DERIVATIVES-PC-PL						
Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB/DEPARTMENT OF RADIATION ONC/OLOGY, UNIV		2001-05-18	100311 180	21001360		Pending
					United States of America		
Patent	BIOTIN DERIVATIVES-PC-US						
Normal via PCT National Phase	LINDGREN, LARS NILSSON, RUINE	2009-01-31	1992-01-15	92030200.3	2082250		Registered
		2012-01-15	1999-03-31	P992 28902.3	Germany		
Patent	BLOOD HANDLING-EP-DE						
Normal via PCT National Phase	LINDGREN, LARS NILSSON, RUINE	2009-01-31	1992-01-15	92030200.3	2082241		Registered
		2012-01-15	1999-03-31	997 514	Denmark		
Patent	BLOOD HANDLING-EP-DK						
Normal via PCT National Phase	LINDGREN, LARS NILSSON, RUINE	2009-01-31	1992-01-15	92030200.3	2082247		Registered
		2012-01-15	1999-03-31	997 514	Spain		
Patent	BLOOD HANDLING-EP-ES						
Normal via PCT National Phase	LINDGREN, LARS NILSSON, RUINE	2009-01-31	1992-01-15	92030200.3	2082242		Registered
		2012-01-15	1999-03-31	997 514	France		
Patent	BLOOD HANDLING-EP-FR						
Normal via PCT National Phase	LINDGREN, LARS NILSSON, RUINE	2009-01-31	1992-01-15	92030200.3	2082248		Registered
		2012-01-15	1999-03-31	997 514	United Kingdom		
Patent	BLOOD HANDLING-EP-GB						
Normal via PCT National Phase	LINDGREN, LARS NILSSON, RUINE	2009-01-31	1992-01-15	92030200.3	2082243		Registered
		2012-01-15	1999-03-31	997 514	Italy		
Patent	BLOOD HANDLING-EP-IT						

Property Category Sub Type	Applicant/Owner Type of Mark Your Reference / Trademark	Reg. No. Duration	Filing Date Reg. Date	App. No. Class	File No. Country	Handled by	Status
Patent EP Validation	LINDGREEN, LARS NILSSON, RUNE	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882345 Netherlands	DH	Registered
Patent EP Validation	BLODBEHANDLING-EP-IL	2008-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	LINDGREEN, LARS NILSSON, RUNE	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	BLODBEHANDLING-EP-SE	2008-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	LINDGREEN, LARS NILSSON, RUNE	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	BLODBEHANDLING-EP-CA	2008-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	LINDGREEN, LARS NILSSON, RUNE	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	BLODBEHANDLING-EP-JP	2008-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	BLODBEHANDLING-EP-US	2008-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	CV-0038-PC-US-I	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	CV-0038-PC-US-II	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	KOLONNEUS-EP-DE	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	KOLONNEUS-EP-DK	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	KOLONNEUS-EP-ES	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	KOLONNEUS-EP-FR	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered
Patent EP Validation	KOLONNEUS-EP-GB	2009-01-31 2012-01-15	1992-01-15 1995-03-31	82033202.3 597 514	2882349 Sweden	DH	Registered

Property Category Sub-Type	Applicant/Owner Type of Mark Your Reference / Trademark	Req. No. Duration	Filing Date Reg. Date	Appl. No. Res. No.	File No. Country	Status Stand- by
Patient EP Validation	MITRA MEDICAL TECHNOLOGY AB	2006-01-31 2019-01-14	1899-01-14 2003-10-15	9650077.1 1,048,493	21008954 Italy	Registered
Patient EP Validation	KOLONNEHUS-EP-IT					
Patient EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2019-01-14	1999-01-14 2003-10-15	9940077.1 1,049,499	21003600 Norway	Registered
Patient EP Validation	KOLONNEHUS-EP-NL					
Patient EP Validation	MITRA MEDICAL TECHNOLOGY AB	2009-01-31 2019-01-14	1999-01-14 2003-10-15	9940077.1 1,049,499	21006665 Sweden	Registered
Patient Normal	KOLONNEHUS-EP-BE					
Patient Normal	MITRA MEDICAL TECHNOLOGY AB	2009-01-14 2019-01-14	1899-01-14 2001-11-15	17775.98 736,828	21006667 Australia	Registered
Patient Normal	KOLONNEHUS-P-AU					
Patient Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB	2009-01-14 2019-01-14	1899-01-14 2001-11-15	17775.98 736,828	21006667 Canada	Pending
Patient Normal via PCT National Phase	KOLONNEHUS-PC-CA					
Patient Normal via PCT National Phase	MITRA MEDICAL TECHNOLOGY AB	2009-01-14 2019-01-14	1999-01-14 2004-08-04	99,803,802.4 99,803,802	20026007 China	Registered
Patient Normal	KOLONNEHUS-PC-CN					
Patient Normal via PCT National Phase	MITRA MEDICAL AB	2009-01-14 2019-01-14	1999-01-14 2006-02-21	137,302 137,302	21003844 Israel	Registered
Patient Normal	KOLONNEHUS-PC-IL					
Patient Normal	MITRA MEDICAL TECHNOLOGY AB	2010-11-06 2020-08-06	2000-09-09 2003-05-26	626,800,446 6,658,543	21028378 United States of America	Registered
Patient Normal	KOLONNEHUS-PC-US					
Patient Normal	MITRA MEDICAL TECHNOLOGY AB	2008-01-14 2019-01-14	1999-01-14 2003-11-02	2000121958 216,544	21006669 Russian Federation	Registered
Patient EP Validation	MITRA MEDICAL AB	2008-09-30 2023-09-02	2003-09-02 2007-09-01	1,037,938.3 1,651,494	21004673 Belgium	Registered
Patient EP Validation	NEW COMPOSITION-EP-BE					
Patient EP Validation	MITRA MEDICAL AB	2008-09-30 2023-09-02	2003-09-02 2007-09-01	1,037,938.3 1,651,494	21004671 Germany	Registered
Patient EP Validation	NEW COMPOSITION-EP-DE					
Patient EP Validation	MITRA MEDICAL AB	2008-09-30 2023-09-02	2003-09-02 2007-09-01	1,037,938.3 1,651,494	21004670 Denmark	Registered
Patient EP Validation	NEW COMPOSITION-EP-DK					

Property Category Sub Type	Applicant/Owner Type of Mark Your Reference / Trademark	Re/date Duration	Filing date Reg. date	Appl. No Reg. No	File No Country	Handled by	Status
Patent EP Validation	MITRA MEDICAL AB NEW COMPOSITION-EP-FR	2008-09-30 2023-09-02	2008-09-02 2007-08-01	03754388.3 1 551 464	21034668 France	ATX	Registered
Patent EP Validation	MITRA MEDICAL AB NEW COMPOSITION-EP-GB	2008-09-30 2023-09-02	2008-09-02 2007-08-01	03754388.3 1 551 464	21034387 United Kingdom	ATX	Registered
Patent EP Validation	MITRA MEDICAL AB NEW COMPOSITION-EP-IE	2008-09-30 2023-09-02	2008-09-02 2007-08-01	03754388.3 1 551 464	21034365 Ireland	ATX	Registered
Patent EP Validation	MITRA MEDICAL AB NEW COMPOSITION-EP-IT	2008-09-30 2023-09-02	2008-09-02 2007-08-01	03754388.3 1 551 464	21034663 Italy	ATX	Registered
Patent EP Validation	MITRA MEDICAL AB NEW COMPOSITION-EP-NL	2008-09-30 2023-09-02	2008-09-02 2007-08-01	03754388.3 1 551 464	21034662 Netherlands	ATX	Registered
Patent EP Validation	MITRA MEDICAL AB NEW COMPOSITION-EP-SE	2008-09-30 2023-09-02	2008-09-02 2007-08-01	03754388.3 1 551 464	21034380 Sweden	ATX	Registered
Patent Normal	MITRA MEDICAL AB NEW COMPOSITION-F-NO	2008-09-30 2023-09-02	2008-09-02 2006-11-29	2006 1671 202883	21023986 Norway	ATX	Pending
Patent Normal via PCT National Phase	MITRA MEDICAL AB TARGETING OF ERB ANTIGENS-PC-AU	2008-11-26 2024-11-26	2004-11-26	2004 262833	21026311 Austria	DH	Pending
Patent Normal via PCT National Phase	MITRA MEDICAL AB TARGETING OF ERB ANTIGENS-PC-CA	2008-11-26 2024-11-26	2004-11-26	2 947 435	21026321 Canada	DH	Pending
Patent Normal via PCT National Phase	MITRA MEDICAL AB TARGETING OF ERB ANTIGENS-PC-CN	2008-11-26 2024-11-26	2004-11-26	2004800410.5	21026320 China	DH	Pending
Patent Normal via PCT National Phase	MITRA MEDICAL AB TARGETING OF ERB ANTIGENS-PC-EP	2008-11-26 2024-11-26	2004-11-26	04800410.5	21026319 European Patent Office	DH	Pending
Patent Normal via PCT National Phase	MITRA MEDICAL AB TARGETING OF ERB ANTIGENS-PC-IN	2008-11-26 2024-11-26	2004-11-26	1871/CHEN/2005	21026318 India	DH	Pending

Property Category Sub-Type	Applicant/Owner Type of Mark Your Reference / Trademark	Replete Duration	Filing/Replete	App/No Reg.No Classes	File No Country	Handl by	Status
Patient Normal via PCT National Phase	MITRA MEDICAL AB		2004-11-25	2003-541102	21028317 Japan	DH	Pending
Patient Normal via PCT National Phase	TARGETING OF ERB ANTIGENS-PC-JP						
Patient Normal via PCT National Phase	MITRA MEDICAL AB		2004-11-25	2003-712945	21028314 Republic of Korea	DH	Pending
Patient Normal via PCT National Phase	TARGETING OF ERB ANTIGENS-PC-KR						
Patient Normal via PCT National Phase	MITRA MEDICAL AB		2004-11-25	PAU200306009	21028316 Mexico	DH	Pending
Patient Normal via PCT National Phase	TARGETING OF ERB ANTIGENS-PC-AU						
Patient Normal via PCT National Phase	MITRA MEDICAL AB	2003-11-30 2004-11-25	2004-11-25	2003-2410	21028315 Norway	DH	Pending
Patient Normal via PCT National Phase	TARGETING OF ERB ANTIGENS-PC-NO						
Patient Normal via PCT National Phase	MITRA MEDICAL AB		2004-11-25	10356 012	21028312 United States of America	DH	Pending
Patient Normal via PCT National Phase	TARGETING OF ERB ANTIGENS-PC-US						

[illegible]

Abundant

Biotech IgG AB
Status List

JULY 16, 2008

INVENTOR	SERIAL NO.	PATENT NO.	PUBLICATION NO.	STATUS	FILED	ISSUED
310002000.USA	06789,413			ABANDONED	2/7/1997	
33700.003	067619,598			ABANDONED	3/6/2000	
33700.DISC001	11/160,965	US 2005-0271673 A1	Functional Reagent for Conjugation to a Biomolecule	PUBLISHED	7/28/2005	12/8/2005
33700.WC004	06761,213	US 2002-0169624	Stable derivatives of a functional reagent for conjugation to a biomolecule	PUBLISHED	6/16/2001	10/31/2002
33700.WC005	06760,280	US 2001-0023266	Functional reagent for conjugation to a biomolecule	PUBLISHED	12/29/2000	9/20/2001
33700.WC006.COM	11516,419	US 2007-0071673 A1	Functional reagent for conjugation to a biomolecule	PUBLISHED	9/6/2005	3/29/2007
33700.006			Reusable Extracorporeal Columns Loaded with Ureic-Obolol Conjugates			
33700.009	10533,968	US 2004-0052784	Antilymphoma Targeting Agents with Effector and Affinity Functions Linked by a Trifunctional Reagent	PUBLISHED	4/23/2003	3/19/2004
33700.010	10596,012	US 2008-0272598 A1	Targeting of ERS Antigens	PUBLISHED	6/10/2005	10/5/2006
337XX	10795,025		Macromolecule Conjugate	PENDING	5/25/2006	
				EXPIRED	1/1/2008	
MIT.01a*	9107142.0		A Method and a System for Enhanced In Vivo Clearance of Diagnostic and/or Therapeutic Agents by Extracorporeal Depletion, and the Use of Said Agents for Said Purposes	ABANDONED	1/17/1991	
MIT.01		PC7756200020	A Method and a System for Enhanced In Vivo Clearance of Diagnostic and/or Therapeutic Agents by Extracorporeal Depletion, and the Use of Said Agents for Said Purposes	PUBLISHED	1/15/1992	9/6/1992
MIT.01US	067690,047	6,251,394	A Method and a System for Enhanced In Vivo Clearance of Diagnostic and/or Therapeutic Agents by Extracorporeal Depletion, and the Use of Said Agents for Said Purposes	ISSUED	10/12/1993	6/26/2001
MIT.002	107238,694		Method of Treatment with Medical Agents	ABANDONED	8/2/1989	

Bioeth IgG AB
Status List

July 16, 2008

MITT	SERIAL NO.	PATENT NO.	TITLE	STATUS	DATE	EXPIRATION
MIT 02	07/662,009	5,474,772	Agents Method of Treatment with Medical	ISSUED	8/2/1990	12/12/1996
MIT 02.1	08/034,889	8,046,225	Agents Method of Treatment with Medical	ISSUED	5/4/1995	4/4/2000
MIT 03	09/693,421	5,723,318	Targeting of Biomolecules Anti-viral Agents with Effector and Activity Functions Linked by a Trifunctional Reagent	ISSUED	10/12/2000	4/20/2004
PC-21007191	PCT/SE03/001949					
PC-21017441	PCT/SE04/001763	WO 04/054615		PUBLISHED	12/12/2003	
UNIV 0029	600611,321	WO 05/051424	Targeting of ERBB Antigens	PUBLISHED	11/26/2004	
			Water Soluble Biotin Derivatives	EXPIRED	2/8/1996	
			A Method and a System for Enhanced In Vivo Clearance of Diagnostic and/or Therapeutic Agents by Extracorporeal Depletion, and the Use of Said Agents for Said Purpose	PENDING		
IN 4834-004	PCT/SE07/02231					

Patenter og patentansøgninger i navnet: Mitra Medical Technology AB

Chas. Hude ref.	Land	Ansøgningssnr.	Patentnr.	Udsættelsesdato	Udløb
72473	AU	17775/99	736826	15. November 2031	14. Januar 2001
72474	CA	2.318.316	2.318.316	10. april 2007	14. Januar 2001
72475	CN	99803802.4	99803802.4	4. august 2004	14. Januar 2001
72477	IL	137.302	137.302	21. februar 2005	14. Januar 2001
72478	JP	2000-539881		Under behandling. Ny officiel behandlingsskrivelse modtaget 14. juli 2008	14. Januar 2001
72479	NO	20033654	318319	19. September 2005	14. Januar 2001
72480	RU	2000121968	2215544	10. November 2003	14. Januar 2001
72481	US	600.446	6.558.543	6. maj 2003	14. Januar 2001
78064	AT	99900077.1	E 251.230	15. oktober 2003	14. Januar 2001
78065	BE	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78066	CH	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78067	CY	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78068	DE	99900077.1	699 12 096.9	15. oktober 2003	14. Januar 2001
78069	DK	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78070	ES	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78071	FI	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78072	FR	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78073	GB	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78074	GR	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78075	IE	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78076	IT	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78077	LU	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78078	MC	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78079	NL	99900077.1	1049499	15. oktober 2003	14. Januar 2001

78080		PT	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78081		SE	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78082		AL	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78083		LT	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78084		LV	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78085		MK	99900077.1	901219	15. oktober 2003	14. Januar 2001
78086		RO	99900077.1	1049499	15. oktober 2003	14. Januar 2001
78087		SI	99900077.1	1049499	15. oktober 2003	14. Januar 2001